8-K/AExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K/A Report, Exhibit Filing (Apr 16, 2014)

Filed April 16, 2014For Securities:TMO

Summary

This filing is an amendment to a previous Current Report on Form 8-K, primarily serving to include the audited financial statements of Life Technologies Corporation. These statements, covering the years ended December 31, 2013 and 2012, are crucial for investors to understand the financial performance and position of the acquired entity prior to its integration with Thermo Fisher Scientific. The filing also includes pro forma financial information, offering a combined view as if the acquisition had occurred earlier, which aids in assessing the overall financial impact of the transaction. The inclusion of these detailed financial statements and pro forma data is a key step in complying with regulatory requirements following a significant acquisition. Investors should review these documents to gauge the financial health and operational scale of Life Technologies, which is now part of Thermo Fisher Scientific, and to evaluate the potential accretion or dilution from this significant strategic move.

Key Highlights

  • 1Inclusion of audited financial statements for Life Technologies Corporation for fiscal years 2013 and 2012.
  • 2Filing of unaudited pro forma condensed combined financial statements as of and for the year ended December 31, 2013.
  • 3These documents are being filed as Exhibit 99.2 and Exhibit 99.3, respectively.
  • 4The filing is an amendment (8-K/A) to a previous report, indicating supplementary financial disclosures.
  • 5The financial statements for Life Technologies cover standard components: auditor's report, balance sheets, income statements, comprehensive income, stockholders' equity, and cash flows.
  • 6The pro forma information aims to provide a combined financial perspective post-acquisition.

Frequently Asked Questions

This amended 8-K (8-K/A) is being filed to provide the necessary audited financial statements of Life Technologies Corporation and pro forma financial information related to the acquisition of Life Technologies. These are required disclosures following a significant business combination.

The filing includes the Report of Independent Auditors, Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Comprehensive Income, Consolidated Statements of Stockholders' Equity, Consolidated Statements of Cash Flows, and Notes to Consolidated Financial Statements, all for the years ended December 31, 2013 and 2012.

The unaudited pro forma condensed combined financial statements present a combined financial picture as if the acquisition of Life Technologies by Thermo Fisher Scientific had occurred at an earlier date. This helps investors understand the potential combined financial impact of the transaction on Thermo Fisher's results.

No, the primary financial statements included here are those of the acquired company, Life Technologies, for 2012 and 2013. The pro forma statements offer a combined view, but Thermo Fisher's own consolidated financial statements for these periods would have been reported in their regular filings.